

P03-311

EVOLUTION OF SUBJECTIVE WELL-BEING IN PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER. 4D STUDY

J. Sanjuan<sup>1</sup>, E. Prieto<sup>2</sup>, J. Galan<sup>3</sup>, B. Manuel<sup>4</sup>

<sup>1</sup>Valencia University, CIBERSAM, INCLIVA, Valencia, <sup>2</sup>AstraZeneca Farmaceutica Spain, <sup>3</sup>CNS Area, Medical Department, AstraZeneca Farmaceutica Spain, Madrid, <sup>4</sup>University of Oviedo, Oviedo, Spain

Introduction: The subjective well-being has been associated with dropouts of treatment and relapses.

Objectives: Determine baseline variables associated with a positive evolution in subjective well-being (increase of 20% and  $\geq 10$  points in subjective SWN-K). Assess the relationship between SWN-K and compliance of treatment.

Methods: Non-interventional, prospective (6 months) study of a cohort of patients with schizophrenia or schizoaffective disorders who have had a clinical relapse that required a change in therapeutic strategy.

Results: 305 patients were included, 288 (94.4%) was the population analyzed and 272 (89.1%) completed the follow-up. 226 (78.5%) of patients have a diagnosis of schizophrenia, the rest were diagnosed of schizoaffective disorder.

Mean total scores in SWN-K were statistically significant in every visit vs. baseline (69.5, 75.5, 77.8 and 80.0). All subscales (social, physical, emotional, mental and self-control) showed a parallel evolution. This progress was associated with compliance according to the evaluations by the psychiatrist, family and patient.

SWN-K	CDSS	PANSS	DAI-10	ICG-G
Month_1	-0.47896**	-0.52412**	0.21840*	-0.41270**
Month_3	-0.44568**	-0.50076**	0.34525**	-0.45590**
Month_6	-0.55217**	-0.48955**	0.33056**	-0.44862**
*p=0.002; **p<0.001				

[Correlation between evolution of SWN-K and:]

Baseline variables associated to positive response in SWN-K in logistic regression were: gender (female) and depressive symptoms (CDSS).

Conclusions: Progress in SWN-K score was related to compliance. Depressive symptoms and gender are the only variables at baseline associated with positive response in SWN-K.

Study sponsored by AstraZeneca Spain